恩替卡韦联合细胞因子诱导的杀伤细胞序贯治疗慢性乙型肝炎患者树突状细胞相关功能观察
发布时间：2018-10-29 12:16
【摘要】：观察恩替卡韦联合细胞因子诱导的杀伤细胞(cytokine-induced kill cells,CIK)序贯治疗慢性乙型肝炎患者DC功能变化,为指导CIK联合核苷(类)药物抗病毒治疗提供理论依据。以15例接受恩替卡韦联合CIK序贯治疗的慢性乙型肝炎患者为观察对象,单独接受CIK治疗患者为对照,分别在治疗前、HBVDNA500IU/ml及CIK治疗2周后流式细胞技术测定DC表面共刺激分子CD1a、CD80、CD83及HLA-DR表达水平,同时淋巴细胞增殖实验评估DC细胞功能。结果显示15例恩替卡韦联合CIK序贯治疗患者同治疗前相比在接受恩替卡韦治疗并达到HBVDNA500IU/ml时仅有HLA-DR表达水平高于治疗前,其它共刺激分子标志物及淋巴细胞增殖能力没有显著变化。CIK序贯治疗后DC共刺激分子标志物和HLA-DR水平明显升高,并且淋巴细胞增殖能力也明显升高。单独CIK治疗患者同治疗前比较DC表面分子标志物水平及淋巴细胞增殖能力均无变化,同联合治疗组相比DC标志物水平和淋巴细胞增殖能力均低于联合治疗组。以上结果提示恩替卡韦联合CIK序贯治疗明显提高慢性乙型肝炎患者DC共刺激分子及HLA-DR表达,并诱导免疫细胞应答功能,恩替卡韦联合CIK序贯治疗可能通过增强DC相关功能提高慢性乙肝患者的抗病毒疗效。
[Abstract]:To observe the changes of DC function in patients with chronic hepatitis B treated by entecavir combined with cytokine induced killer cells (cytokine-induced kill cells,CIK), and to provide a theoretical basis for the guidance of CIK combined with nucleoside (nucleoside) antiviral therapy. Fifteen patients with chronic hepatitis B who received entecavir plus CIK sequential therapy, and 15 patients treated with CIK alone as control, were observed before treatment. After two weeks of treatment with HBVDNA500IU/ml and CIK, the expression levels of CD1a,CD80,CD83 and HLA-DR on DC surface were measured by flow cytometry, and the function of DC cells was evaluated by lymphocyte proliferation assay. The results showed that the expression level of HLA-DR in 15 patients with entecavir combined with CIK was higher than that before treatment when they were treated with entecavir and reached HBVDNA500IU/ml. There was no significant change in other costimulatory molecular markers and lymphocyte proliferation ability. After CIK sequential therapy, the levels of DC costimulatory molecular markers and HLA-DR were significantly increased, and the lymphocyte proliferation ability was also significantly increased. There was no change in the level of DC surface molecular markers and lymphocyte proliferation in patients treated with CIK alone. Compared with the combined treatment group, the level of DC markers and the ability of lymphocyte proliferation were lower than those of the combined treatment group. These results suggest that the sequential therapy of entecavir and CIK can significantly increase the expression of DC costimulatory molecules and HLA-DR and induce immune cell response in patients with chronic hepatitis B. Entecavir combined with CIK sequential therapy may enhance the antiviral efficacy of chronic hepatitis B patients by enhancing DC related function.
【作者单位】： 南京军区福州总医院感染科;福建医科大学福总临床医学院传染病学教研室;
【基金】：福建省自然科学基金项目(2011J01236)
【分类号】：R512.62
[Abstract]:To observe the changes of DC function in patients with chronic hepatitis B treated by entecavir combined with cytokine induced killer cells (cytokine-induced kill cells,CIK), and to provide a theoretical basis for the guidance of CIK combined with nucleoside (nucleoside) antiviral therapy. Fifteen patients with chronic hepatitis B who received entecavir plus CIK sequential therapy, and 15 patients treated with CIK alone as control, were observed before treatment. After two weeks of treatment with HBVDNA500IU/ml and CIK, the expression levels of CD1a,CD80,CD83 and HLA-DR on DC surface were measured by flow cytometry, and the function of DC cells was evaluated by lymphocyte proliferation assay. The results showed that the expression level of HLA-DR in 15 patients with entecavir combined with CIK was higher than that before treatment when they were treated with entecavir and reached HBVDNA500IU/ml. There was no significant change in other costimulatory molecular markers and lymphocyte proliferation ability. After CIK sequential therapy, the levels of DC costimulatory molecular markers and HLA-DR were significantly increased, and the lymphocyte proliferation ability was also significantly increased. There was no change in the level of DC surface molecular markers and lymphocyte proliferation in patients treated with CIK alone. Compared with the combined treatment group, the level of DC markers and the ability of lymphocyte proliferation were lower than those of the combined treatment group. These results suggest that the sequential therapy of entecavir and CIK can significantly increase the expression of DC costimulatory molecules and HLA-DR and induce immune cell response in patients with chronic hepatitis B. Entecavir combined with CIK sequential therapy may enhance the antiviral efficacy of chronic hepatitis B patients by enhancing DC related function.
【作者单位】： 南京军区福州总医院感染科;福建医科大学福总临床医学院传染病学教研室;
【基金】：福建省自然科学基金项目(2011J01236)
【分类号】：R512.62
【参考文献】
相关期刊论文 前3条
1 陈月;陈洪涛;吴诗品;周雅莹;方爱萍;;阿德福韦酯对慢性乙型肝炎患者外周血树突状细胞和淋巴细胞亚群的影响[J];广东医学;2010年01期
2 庄捷;曹晖;刘祥麟;张尚权;;树突状细胞与CIK细胞共培养诱生的DCCIK细胞群对肿瘤的杀伤作用[J];细胞生物学杂志;2007年02期
3 韩际奥;杨丽;王志凌;韩莉;王郁杰;马英杰;;慢性乙型肝炎患者DC/CIK体外经HBsAg活化后自体回输的疗效和对机体免疫的影响[J];中华实验和临床感染病杂志(电子版);2013年03期
【共引文献】
相关期刊论文 前10条
1 侯金程;杨丽辉;杨琨;谷京城;;树突状细胞疫苗联合细胞因子诱导的杀伤细胞治疗鼻腔及鼻窦恶性黑色素瘤的近期疗效观察[J];临床医学;2010年01期
2 程岩;耿家宝;隋云华;张s，
本文编号：2297672
本文链接：https://www.wllwen.com/yixuelunwen/xiaohjib/2297672.html
最近更新
教材专著
